8-K: Werewolf Therapeutics Announces Promising Initial Results from Phase 1 Trial of WTX-330

Werewolf Therapeutics reports encouraging early data from its Phase 1 trial of WTX-330, showing improved tolerability and clinical activity in advanced cancer patients.

Summary

• Werewolf Therapeutics announced initial results from its Phase 1 clinical trial of WTX-330, a conditionally activated interleukin-12 (IL-12) molecule.
• The trial included patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma who had relapsed or were refractory to standard therapies.
• Eleven patients were dosed in the dose escalation phase across three cohorts: 0.016 mg/kg, 0.024 mg/kg, and 0.032 mg/kg, and two patients in dose expansion at 0.024 mg/kg.
• WTX-330 at 0.024 mg/kg demonstrated a 23-fold higher systemic drug concentration of IL-12 prodrug compared to previous IL-12 therapies at their maximum tolerated dose.
• One patient with metastatic melanoma achieved an unconfirmed partial response after eight weeks of treatment at 0.024 mg/kg.
• Two patients with microsatellite stable colorectal cancer achieved stable disease, one for 24 weeks, at 0.032 mg/kg.
• The treatment showed evidence of increased antitumor CD8+ T and natural killer cell activity.
• All patients experienced mild to moderate treatment-related toxicities, primarily associated with the first dose.
• Two patients experienced reversible dose-limiting toxicities at the 0.032 mg/kg dose level.
• Two expansion arms have been opened to evaluate 0.024 mg/kg of WTX-330 in patients with immune checkpoint inhibitor-resistant tumors and those for whom ICI blockade is not approved.

Sentiment

Score: 8

Explanation: The document presents positive initial results from a Phase 1 trial, showing improved tolerability and clinical activity. While there are risks and uncertainties, the overall tone is optimistic and suggests potential for future success.

Positives

• WTX-330 demonstrated a significantly higher systemic drug concentration compared to previous IL-12 therapies.
• The treatment showed promising clinical activity, including a partial response in a melanoma patient and stable disease in colorectal cancer patients.
• There was evidence of robust activation of immune biomarkers, indicating the drug's mechanism of action is working.
• The tolerability profile was manageable, with no Grade 4 or 5 adverse events reported.
• The expansion arms of the trial will allow for further evaluation of WTX-330 in different patient populations.

Negatives

• Two patients experienced reversible dose-limiting toxicities at the 0.032 mg/kg dose level.
• The partial response in the melanoma patient is unconfirmed and requires a confirmatory scan.
• The maximum tolerated dose has not yet been established.

Risks

• The results are preliminary and based on a small number of patients.
• The partial response is unconfirmed and may not be sustained.
• The treatment-related toxicities, although mild to moderate, could become more severe with higher doses or in a larger patient population.
• The development of WTX-330 is subject to the risks and uncertainties inherent in clinical trials and regulatory approvals.

Future Outlook

The company anticipates presenting further safety, biomarker, and antitumor activity from patients enrolled in expansion arms at a medical meeting in the fourth quarter of 2024.

Management Comments

• Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, stated that the preliminary clinical data show promising tolerability and signals of efficacy of WTX-330 in heavily pretreated patients with late-stage solid tumors.
• Randi Isaacs, M.D., Chief Medical Officer of Werewolf, believes this is the first time that clinical benefit using a full-potency, systemically delivered, IL-12 molecule has been observed at therapeutically relevant doses with fewer severe toxicity-related events in an outpatient setting.

Industry Context

The announcement is significant as it addresses the historical limitations of IL-12 therapy, which has been hampered by severe toxicity. Werewolf's approach of using a conditionally activated IL-12 molecule aims to overcome these limitations and potentially provide a more effective treatment option for cancer patients.

Comparison to Industry Standards

• Previous IL-12 therapies, such as recombinant human IL-12 (rhIL-12) at 500 ng/kg, have been limited by severe toxicities.
• WTX-330 at 0.024 mg/kg demonstrated a 23-fold higher systemic drug concentration of IL-12 prodrug compared to the maximum tolerated dose of rhIL-12.
• The observed partial response in a melanoma patient and stable disease in colorectal cancer patients are encouraging compared to the limited efficacy seen with previous IL-12 therapies.
• The tolerability profile of WTX-330 appears improved compared to historical data for rhIL-12, with no Grade 4 or 5 adverse events reported.

Stakeholder Impact

• Shareholders may view the positive initial results as a positive development for the company.
• Patients with advanced cancer may see WTX-330 as a potential new treatment option.
• Employees of Werewolf Therapeutics may be encouraged by the progress of the clinical trial.

Next Steps

• The company will continue to enroll patients in the expansion arms of the Phase 1 trial.
• Further safety, biomarker, and antitumor activity data will be presented at a medical meeting in the fourth quarter of 2024.
• A confirmatory scan is pending for the melanoma patient who achieved a partial response.

Key Dates

Keywords

WTX-330, Interleukin-12, IL-12, Cancer, Immunotherapy, Clinical Trial, Phase 1, Oncology, Tumor, Metastatic, Melanoma, Colorectal Cancer, Non-Hodgkin Lymphoma, INDUKINE, Biomarkers